Short answer
Spyre Therapeutics, Inc. (SYRE) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$11M
- +83.8% YoY · +69.5% QoQ
- EPS (diluted)
- −$0.15
- +89.4% YoY · +86.2% QoQ
Source: XBRL data from the Spyre Therapeutics, Inc. (SYRE) Q3 2025 10-Q on SEC EDGAR. USD.
Spyre Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New material weakness in internal controls discovered Q4 2024 led to restatements of prior net loss per share disclosures
- Going concern risk heightened by potential difficulty raising capital amid macroeconomic volatility and intensified biotech funding competition
- FDA and other government agency disruptions, including potential shutdowns, may delay clinical trial review and product approvals
- Intense competition from larger biopharma firms and emerging companies threatens clinical trial recruitment and future market penetration
- Cash, cash equivalents, and marketable securities totaled $486.2 million as of September 30, 2025, with ongoing capital needs to fund operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Spyre Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.